Back to Search
Start Over
Generation and characterization of the Eµ-Irf8 mouse model.
- Source :
-
Cancer genetics [Cancer Genet] 2020 Jul; Vol. 245, pp. 6-16. Date of Electronic Publication: 2020 Jun 03. - Publication Year :
- 2020
-
Abstract
- In mature B-cell malignancies, chromosomal translocations often juxtapose an oncogenic locus to the regulatory regions of the immunoglobulin genes. These genomic rearrangements can associate with specific clinical/pathological sub-entities and inform diagnosis and treatment decisions. Recently, we characterized the t(14;16)(q32;q24) in diffuse large B-cell lymphoma (DLBCL), and showed that it targets the transcription factor IRF8, which is also somatically mutated in ~10% of DLBCLs. IRF8 regulates innate and adaptive immune responses mediated by myeloid/monocytic and lymphoid cells. While the role of IRF8 in human myeloid/dendritic-cell disorders is well established, less is known of its contribution to the pathogenesis of mature B-cell malignancies. To address this knowledge gap, we generated the Eµ-Irf8 mouse model, which mimics the IRF8 deregulation associated with t(14;16) of DLBCL. Eµ-Irf8 mice develop normally and display peripheral blood cell parameters within normal range. However, Eµ-Irf8 mice accumulate pre-pro-B-cells and transitional B-cells in the bone marrow and spleen, respectively, suggesting that the physiological role of Irf8 in B-cell development is amplified. Notably, in Eµ-Irf8 mice, the lymphomagenic Irf8 targets Aicda and Bcl6 are overexpressed in mature B-cells. Yet, the incidence of B-cell lymphomas is not increased in the Eµ-Irf8 model, even though their estimated survival probability is significantly lower than that of WT controls. Together, these observations suggest that the penetrance on the Irf8-driven phenotype may be incomplete and that introduction of second genetic hit, a common strategy in mouse models of lymphoma, may be necessary to uncover the pro-lymphoma phenotype of the Eµ-Irf8 mice.<br />Competing Interests: Declaration of Computing Interest The authors declare no competing financial interests. Data availability: The data that support the findings of this study are available in the main manuscript, supplementary materials and can be requested from the corresponding author.<br /> (Published by Elsevier Inc.)
Details
- Language :
- English
- ISSN :
- 2210-7762
- Volume :
- 245
- Database :
- MEDLINE
- Journal :
- Cancer genetics
- Publication Type :
- Academic Journal
- Accession number :
- 32535543
- Full Text :
- https://doi.org/10.1016/j.cancergen.2020.05.002